Fibroblasts actively participate in cellular immune responses in connective tissues, when activated by signals abundant at inflammatory sites, i.e. cytokines and bacterial products. This is manifested by the generation of proinflammatory cytokines and by presenting antigens to proliferating T cells. The array of cytokines generated by immune-activated fibroblasts is determined by the stimulant and is controlled at multiple regulatory levels, such as transcription, translation, posttranslational modifications, the signal transduction pathways which are activated, the timing of expression as well as compartmentation within the producing cell. In general, cytokines with potential of tissue damage, i.e. IL-1 alpha and, to a lesser extent, IL-6, are more tightly regulated than cytokines with restricted target cell specificity (i.e. CSFs). Deviations in the pattern of expression of IL-1 alpha in pathological conditions affecting connective tissues are described; a long-lasting suppression of IL-1 alpha production was observed in dermal fibroblasts of mice suffering from chronic graft-vs.-host disease (cGVHD), while some oncogene-transformed fibroblastoid cell lines were shown to generate this cytokine in a constitutive manner and as a result expressed reduced tumorigenicity. The latter is due to the adjuvant effects of IL-1 alpha, expressed by the malignant cells, which induce potent antitumor specific immune responses which ultimately lead to its eradication. Understanding the molecular mechanisms which control cytokine production in fibroblasts may enrich our knowledge of connective tissue homeostasis and deviations from it in pathological states. The latter may also lead to the development of novel therapeutical means for controlling chronic inflammatory diseases or malignancies.

Department of Microbiology and Immunology Faculty of Health Sciences Ben Gurion University of the Negev Beer Sheva Israel

Zobrazit více v PubMed

J Cell Biol. 1988 Aug;107(2):447-56 PubMed

Immunol Today. 1991 Jan;12(1):17-23 PubMed

FASEB J. 1990 Aug;4(11):2860-7 PubMed

Int J Cancer. 1992 Jul 9;51(5):822-30 PubMed

J Immunol. 1992 Nov 15;149(10):3254-9 PubMed

Int J Cancer. 1992 Feb 1;50(3):450-7 PubMed

Cell. 1993 Nov 19;75(4):653-60 PubMed

Proc Natl Acad Sci U S A. 1972 Jun;69(6):1408-12 PubMed

Nature. 1989 May 4;339(6219):27-30 PubMed

Immunol Lett. 1993 Dec;39(1):45-52 PubMed

J Cell Physiol. 1965 Dec;66(3):319-24 PubMed

Eur Cytokine Netw. 1994 Nov-Dec;5(6):573-92 PubMed

Eur Cytokine Netw. 1990 May-Jun;1(2):77-83 PubMed

Cytokine. 1993 Jan;5(1):47-56 PubMed

Proc Natl Acad Sci U S A. 1985 Feb;82(4):1204-8 PubMed

Eur Cytokine Netw. 1994 Nov-Dec;5(6):547-61 PubMed

Immunol Today. 1986 Oct;7(10):303-7 PubMed

Eur Cytokine Netw. 1994 Nov-Dec;5(6):563-71 PubMed

Isr J Med Sci. 1992 Feb;28(2):133-6 PubMed

Eur Cytokine Netw. 1994 Nov-Dec;5(6):517-31 PubMed

Folia Biol (Praha). 1992;38(3-4):240-57 PubMed

Folia Biol (Praha). 1994;40(1-2):1-18 PubMed

Int J Cancer. 1992 Feb 1;50(3):443-9 PubMed

N Engl J Med. 1993 Jan 14;328(2):106-13 PubMed

Blood. 1991 Mar 15;77(6):1131-45 PubMed

J Immunol. 1984 Sep;133(3):1339-45 PubMed

Eur Cytokine Netw. 1991 Aug-Sep;2(4):257-64 PubMed

Immunol Today. 1986 Feb;7(2):45-56 PubMed

Eur J Immunol. 1990 Apr;20(4):731-8 PubMed

Science. 1986 Aug 1;233(4763):566-9 PubMed

Isr J Med Sci. 1995 Jan;31(1):2-5 PubMed